Sanofi (NASDAQ:SNY) Shares Bought by Altrius Capital Management Inc

Altrius Capital Management Inc grew its position in shares of Sanofi (NASDAQ:SNY) by 5.1% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 161,940 shares of the company’s stock after acquiring an additional 7,865 shares during the quarter. Sanofi comprises 2.1% of Altrius Capital Management Inc’s portfolio, making the stock its 5th biggest position. Altrius Capital Management Inc’s holdings in Sanofi were worth $7,810,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in SNY. Charles Schwab Investment Management Inc. lifted its stake in Sanofi by 31.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 139,505 shares of the company’s stock worth $8,040,000 after purchasing an additional 33,105 shares during the last quarter. Arkadios Wealth Advisors raised its position in Sanofi by 19.0% during the fourth quarter. Arkadios Wealth Advisors now owns 4,709 shares of the company’s stock valued at $227,000 after buying an additional 751 shares during the period. Geode Capital Management LLC boosted its stake in shares of Sanofi by 7.1% during the 3rd quarter. Geode Capital Management LLC now owns 254,738 shares of the company’s stock valued at $14,681,000 after buying an additional 16,780 shares during the period. JPMorgan Chase & Co. increased its holdings in Sanofi by 20.9% in the third quarter. JPMorgan Chase & Co. now owns 2,310,809 shares of the company’s stock worth $133,172,000 after buying an additional 399,301 shares during the last quarter. Finally, GFS Advisors LLC lifted its position in shares of Sanofi by 1,017.9% in the third quarter. GFS Advisors LLC now owns 12,800 shares of the company’s stock worth $738,000 after buying an additional 11,655 shares during the last quarter. 14.04% of the stock is owned by hedge funds and other institutional investors.

Sanofi Price Performance

Shares of NASDAQ SNY opened at $54.14 on Friday. Sanofi has a twelve month low of $45.22 and a twelve month high of $58.97. The company has a market cap of $137.40 billion, a PE ratio of 21.74, a price-to-earnings-growth ratio of 1.01 and a beta of 0.57. The business’s 50 day moving average price is $51.51 and its two-hundred day moving average price is $52.59. The company has a quick ratio of 1.14, a current ratio of 1.46 and a debt-to-equity ratio of 0.15.

Sanofi (NASDAQ:SNY) last released its quarterly earnings results on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. On average, analysts predict that Sanofi will post 4.36 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on SNY. Sanford C. Bernstein upgraded Sanofi to a “strong-buy” rating in a research note on Thursday, January 30th. StockNews.com lowered shares of Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Finally, Deutsche Bank Aktiengesellschaft upgraded Sanofi from a “sell” rating to a “hold” rating in a report on Thursday, January 30th. Two equities research analysts have rated the stock with a hold rating, one has issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $60.00.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.